In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Automedics Medical Systems

http://www.automedicsrx.com/

Latest From Automedics Medical Systems

Gene Therapy: What To Expect Now And In The Future

The US FDA could approve as many new gene therapies in 2023 as it has in the previous five years. Development in the field has rapidly accelerated, but still faces hurdles.

FDA Gene Therapy

Gene Therapy: What To Expect Now And In The Future

The US FDA could approve as many new gene therapies in 2023 as it has in the previous five years. Development in the field has rapidly accelerated, but still faces hurdles.

Gene Therapy FDA

Vertex Gains In Vivo CRISPR Foothold With Mammoth Pact

Deal Snapshot: The nearly $700m deal gives Vertex, already with a major foothold in CRISPR, access to Mammoth’s ultra-compact gene-editing technology in two diseases.

Mammoth Biosciences Thinks Ultra-Small As It Attains Elephant-Sized Valuation

The Jennifer Doudna-backed startup got a billion-dollar valuation with VC rounds totaling $195m. CEO Trevor Martin talked with Scrip about Mammoth’s ultra-small CRISPR system technology.

Financing Gene Therapy
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
UsernamePublicRestriction

Register